In the latest quarter, 12 analysts provided ratings for Pacira BioSciences (NASDAQ:PCRX), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 3 | 2 | 1 | 0 |
| Last 30D | 2 | 0 | 1 | 1 | 0 |
| 1M Ago | 2 | 2 | 0 | 0 | 0 |
| 2M Ago | 2 | 1 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $33.25, a high estimate of $57.00, and a low estimate of $10.00. A decline of 25.15% from the prior average price target is evident in the current average.
Deciphering Analyst Ratings: An In-Depth Analysis
The perception of Pacira BioSciences by financial...
Login or create a forever free account to read this news
Sign up/Log in